Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
New England Journal of Medicine2008Vol. 359(21), pp. 2195–2207
Citations Over TimeTop 1% of 2008 papers
Paul M. Ridker, Eleanor Danielson, Francisco Antônio Helfenstein Fonseca, Jacques Genest, Antonio M. Gotto, John J.P. Kastelein, Wolfgang Köenig, Peter Libby, Alberto Lorenzatti, Jean MacFadyen, Børge G. Nordestgaard, James Shepherd, James T. Willerson, Robert J. Glynn
Abstract
In this trial of apparently healthy persons without hyperlipidemia but with elevated high-sensitivity C-reactive protein levels, rosuvastatin significantly reduced the incidence of major cardiovascular events. (ClinicalTrials.gov number, NCT00239681.)
Related Papers
- → An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers(2003)104 cited
- → Effect of rosuvastatin on C-reactive protein and progression of aortic stenosis(2011)25 cited
- → An Economic Evaluation of Rosuvastatin Treatment in Systolic Heart Failure: Evidence from the CORONA Trial(2009)20 cited
- → Rosuvastatin: winner in the statin wars, patients' health notwithstanding(2015)13 cited
- → Impact of the JUPITER Trial on Statin Prescribing for Primary Prevention(2013)5 cited